Scancell Holdings's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 54.5% per year.
Key information
-9.7%
Earnings growth rate
5.6%
EPS growth rate
Biotechs Industry Growth
17.0%
Revenue growth rate
54.5%
Return on equity
n/a
Net Margin
n/a
Last Earnings Update
30 Apr 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Scancell Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:SCNL.F Revenue, expenses and earnings (GBP Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Apr 24
0
-6
5
13
31 Jan 24
0
-8
5
13
31 Oct 23
0
-10
5
13
31 Jul 23
3
-11
5
12
30 Apr 23
5
-12
5
12
31 Jan 23
5
-12
5
11
31 Oct 22
5
-13
5
10
31 Jul 22
3
-9
5
10
30 Apr 22
0
-5
5
9
31 Jan 22
0
-6
5
9
31 Oct 21
0
-8
4
8
31 Jul 21
0
-12
4
7
30 Apr 21
0
-15
3
6
31 Jan 21
0
-11
3
6
31 Oct 20
0
-7
2
5
31 Jul 20
0
-6
2
5
30 Apr 20
0
-6
2
5
31 Jan 20
0
-5
2
4
31 Oct 19
0
-5
2
4
31 Jul 19
0
-5
2
4
30 Apr 19
0
-6
3
4
31 Jan 19
0
-6
3
4
31 Oct 18
0
-5
3
3
31 Jul 18
0
-5
3
3
30 Apr 18
0
-4
2
3
31 Jan 18
0
-4
2
3
31 Oct 17
0
-4
2
3
31 Jul 17
0
-4
2
3
30 Apr 17
0
-4
2
3
31 Jan 17
0
-3
2
3
31 Oct 16
0
-3
1
2
31 Jul 16
0
-3
1
2
30 Apr 16
0
-3
1
2
31 Jan 16
0
-2
1
2
31 Oct 15
0
-2
1
2
31 Jul 15
0
-2
1
2
30 Apr 15
0
-2
1
2
31 Jan 15
0
-2
1
2
31 Oct 14
0
-2
1
2
31 Jul 14
0
-2
1
2
30 Apr 14
0
-2
1
2
Quality Earnings: SCNL.F is currently unprofitable.
Growing Profit Margin: SCNL.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCNL.F is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare SCNL.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCNL.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SCNL.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.